EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

The Effect of Chronic Azithromycin Use in Winter on Health Care Utilization for Children With Bronchopulmonary Dysplasia: A Double Blind Randomized Controlled Study (RCT)

Der Effekt einer chronischen Azithromycin-Anwendung im Winter auf die Inanspruchnahme von Gesundheitsleistungen bei Kindern mit Bronchopulmonaler Dysplasie: doppelblind randomisierte kontrollierte Studie (RCT)

Ricardo A Mosquera iD, Aravind Yadav, Maria Del Mar Romero-Lopez, Ivan G Magana-Ceballos, S Shahrukh Hashmi, Wilfredo De Jesus Rojas, Maria E Tellez, Kaleigh Riggs-Harpur, Fatima M Boricha, Tina S Reddy, Janice L John, Tomika S Harris und 6 weitere

Pediatric Pulmonology · 2025-10 · 60 (10)

DOI: 10.1002/ppul.71314 ↗

Auf einen Blick

Bei 60 Kindern mit Bronchopulmonaler Dysplasie führte Azithromycin über eine Wintersaison nicht zu einer signifikanten Senkung des primären Outcomes. In einer Hochrisikogruppe zeigten sich niedrigere Raten, die Autoren sehen dort einen möglichen Nutzen.

Fragestellung

Senkt Azithromycin im Winter bei Kindern mit Bronchopulmonaler Dysplasie die Inanspruchnahme von Gesundheitsleistungen?

Methode

Single-center, doppelblindes RCT mit 60 Kindern (6 Monate bis 6 Jahre); Azithromycin 5 mg/kg 3-mal/Woche vs. Placebo über eine Wintersaison (Oktober bis März).

Ergebnisse

Primäres Outcome ohne signifikanten Unterschied: unscheduled healthcare visits 14,9 vs. 4,2 pro Kind-Jahr; p = 0,1, IRR = 2,1 (95 %-KI 0,8–5,4). ER-Besuche sanken in der Interventionsgruppe: 0,5 vs. 1,3 pro Kind-Jahr; p = 0,047, IRR = 0,4 (95 %-KI 0,1–0,9).

Einschränkungen

Zwei Ausreißer in der Macrolidgruppe waren > 40 Tage aus nicht-medizinischen Gründen im Krankenhaus.

Schlussfolgerung der Autor:innen

Die Macrolid-Prophylaxe senkte das primäre Outcome der ungeplanten Gesundheitskontakte nicht signifikant; die Subgruppenanalyse spricht jedoch für einen möglichen Nutzen bei Hochrisikokindern.

Kernaussagen

  • Primäres Outcome: kein signifikanter Unterschied zwischen Azithromycin und Placebo
  • ER-Besuche niedriger unter Azithromycin: IRR 0,4 (95 %-KI 0,1–0,9)
  • Hochrisikokinder: 82 % Wahrscheinlichkeit eines Nutzens

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Pulmonology, online erschienen am 15.10.2025. Verfasst von Ricardo A Mosquera und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, McGovern Medical School, Division of Pediatric Pulmonology, The University of Texas Health Science Center at Houston (UTHea…. Hauptthemen laut MEDLINE: Azithromycin, Bronchopulmonary Dysplasia, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: We thank the staff at the High-Risk Children's Clinic and High-Risk Infant Clinic at The University of Texas Health Science Center at Houston for their assista….

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bronchopulmonary dysplasia (BPD), a chronic lung disease in preterm infants, often leads to acute respiratory exacerbations triggered by infections. Our previous mouse study suggested that azithromycin's anti‐inflammatory properties may benefit virus‐induced respiratory illnesses prophylactically.

Methods

In this single‐center, double‐blind RCT, 60 children (6 months to 6 years) with BPD received azithromycin (5 mg/kg three times weekly; n = 30) or placebo ( n = 30) for one winter season (October to March). Primary outcome was the total number of days of unscheduled healthcare clinic visits, ER visits, and hospital days. Secondary outcomes comprised clinic visits, ER visits, hospital admissions, hospital days, and adverse events. Standard frequentist and Bayesian analyses were used.

Results

No significant difference in primary outcomes, unscheduled healthcare visits (macrolides 14.9 vs. 4.2 per child‐year; p = 0.1, IRR = 2.1; 95% CI: 0.8−5.4), Bayesian analysis showing 11% probability of benefit; however, high‐risk children (< 2 years, no tracheostomy), rates were lower with the macrolide group (2.7 vs. 4.6 per child‐year; IRR = 0.6; 95% CI: 0.2–1.5), with an 82% probability of benefit. Two outliers in the macrolide group stayed > 40 days in the hospital for non‐medical reasons. For secondary outcomes, we observe a decrease in the intervention group on ER visits (0.5 vs. 1.3 per child‐year; p = 0.047, IRR = 0.4; 95% CI: 0.1−0.9). Hospital days increased (12.1 vs. 1.2 per child‐year; IRR = 9.3; 95% CI: 5.5−16.8).

Conclusions

Macrolide prophylaxis did not lead to a significant reduction in the primary outcome of unscheduled healthcare encounter days, but subgroup analysis suggests a potential benefit in high‐risk children, with 82% probability of benefit. Trial Registration: NCT02544984.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinBronchopulmonary DysplasiaAnti-Bacterial AgentsHumansMaleFemaleDouble-Blind MethodChild, PreschoolInfantChildSeasonsHospitalizationBayes TheoremEmergency Service, Hospital

Stichwörter der Autor:innen

azithromycinbronchopulmonary dysplasiachronic lung diseasemacrolide

Substanzen

AzithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pediatrics, McGovern Medical School, Division of Pediatric Pulmonology, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, Texas, USA.
  • Department of Pediatrics, McGovern Medical School, Division of Neonatal-Perinatal Medicine, UTHealth Houston, Houston, Texas, USA.
  • Institute for Clinical Research and Learning Health Care, McGovern Medical School, UTHealth Houston, Houston, Texas, USA.
  • Department of Pediatrics, McGovern Medical School, UTHealth Houston, Houston, Texas, USA.
  • Department of Pediatrics, University of Puerto Rico School of Medicine, San Juan, USA.
  • Pediatric Research Center, University of Texas Health Sciences in Houston, Texas, USA.

ORCID-Profile: Ricardo A Mosquera, Carlos E Rodriguez-Martinez, Jefferson Buendia

Förderung

  • We thank the staff at the High-Risk Children's Clinic and High-Risk Infant Clinic at The University of Texas Health Science Center at Houston for their assista…

Zitieren

APA

Mosquera, R. A., Yadav, A., Romero-Lopez, M. D. M., Magana-Ceballos, I. G., Hashmi, S. S., De Jesus Rojas, W., Tellez, M. E., Riggs-Harpur, K., Boricha, F. M., Reddy, T. S., John, J. L., Harris, T. S., Rodriguez-Martinez, C. E., Buendia, J., McBeth, K. E., Jon, C. K., Stark, J. M., & Colasurdo, G. N. (2025). The Effect of Chronic Azithromycin Use in Winter on Health Care Utilization for Children With Bronchopulmonary Dysplasia: A Double Blind Randomized Controlled Study (RCT). Pediatric Pulmonology, 60(10). https://doi.org/10.1002/ppul.71314

Vancouver

Mosquera RA, Yadav A, Romero-Lopez MDM, Magana-Ceballos IG, Hashmi SS, De Jesus Rojas W, et al. The Effect of Chronic Azithromycin Use in Winter on Health Care Utilization for Children With Bronchopulmonary Dysplasia: A Double Blind Randomized Controlled Study (RCT). Pediatric Pulmonology. 2025;60(10). doi:10.1002/ppul.71314

BibTeX
@article{Mosquera2025,
  author = {Mosquera, Ricardo A and Yadav, Aravind and Romero-Lopez, Maria Del Mar and Magana-Ceballos, Ivan G and Hashmi, S Shahrukh and De Jesus Rojas, Wilfredo and Tellez, Maria E and Riggs-Harpur, Kaleigh and Boricha, Fatima M and Reddy, Tina S and John, Janice L and Harris, Tomika S and Rodriguez-Martinez, Carlos E and Buendia, Jefferson and McBeth, Katrina E and Jon, Cindy K and Stark, James M and Colasurdo, Giuseppe N},
  title = {The Effect of Chronic Azithromycin Use in Winter on Health Care Utilization for Children With Bronchopulmonary Dysplasia: A Double Blind Randomized Controlled Study (RCT)},
  journal = {Pediatric Pulmonology},
  year = {2025},
  volume = {60},
  number = {10},
  doi = {10.1002/ppul.71314}
}
Kostenlos starten →